Introduction {#S1}
============

Ischemic heart disease and chronic heart failure (HF) remain major causes of mortality worldwide despite advances made dramatically in therapeutic approaches on neurohormones and devices ([@B27]). "Metabolic modulation" proved to be a promising pharmacological strategy by optimizing cardiac substrate preference given that substrate perturbations might underlie contractile dysfunction and left ventricular (LV) remodeling ([@B30]; [@B5]). However, only few metabolic regulators are available in the clinic, accounting for insufficient evidence. Healthy adult hearts prefer fatty acids (FA) as the predominant energy source for 60--90% of adenosine triphophate (ATP) production ([@B19]). Of importance is that "metabolic flexibility" empowers a normal heart to switch between FA and other alternative substrates, including glucose, ketone bodies, and amino acids, depending on alterations in physiological conditions, thus ensuring continuous contractility ([@B12]; [@B3]). It is generally considered that the failing heart prefers glucose over FA, eliciting a current therapeutic paradigm that increasing glucose oxidation (or depressing FA utilization) is cardioprotective as glucose expends less oxygen for ATP generation ([@B24]; [@B21]). Unexpectedly, either increasing glucose uptake by specific overexpression of GLUT1 in the murine heart ([@B54]) or depriving FA acutely using acipimox ([@B50]) deteriorates cardiac metabolic inflexibility and functional failure. In addition, high fat feeding to increase FA oxidation (FAO) improves LV function in rats with myocardial infarction (MI) ([@B4]). Hence, whether to further promote glucose utilization or normalize substrate to FA still remains unresolved ([@B25]). Currently, agents that stimulate glucose or FA might be tested further as they induce inflexibility. It is cautiously concluded that promoting metabolic extremes, either preference or inhibition for any one substrate, makes the heart further lose its flexibility and become vulnerable to adverse injuries under stressors. FA and glucose metabolism are both indispensable, and recovering substrate flexibility is a more desirable target for long-term metabolic modulation.

Recently, region-dependent LV remodeling after MI invoked great interest for its potential to detect more sensitive variables for prognosis and treatment ([@B42]; [@B45]). According to the proximal--distal axis, the infarcted myocardium is divided into an infarcted area, a border area (adjacent to scar; hypoperfused), and a remote area (distal to scar; perfused) ([@B45]). A series of studies confined the border area to be a discrete zone with hallmarks of unique structural ([@B36]), mechanical ([@B42]), and transcriptional properties ([@B45]) distinct from the remote myocardium. Importantly, metabolic remodeling post-MI is also identified as spatial non-uniformity. The transcriptome and regulatory profiles of mitochondrial oxidative phosphorylation and FAO and glucose metabolism were more perturbed in the border area than in remote areas ([@B35]; [@B45]). It was proposed that the regional modulation of cardiac substrate utilization, that is, selecting the appropriate ones for distinct areas based on their local microenvironment, is a promising target for motivating metabolic flexibility.

Qiliqiangxin capsules (QLQX), a listed traditional Chinese medicine comprising 11 herbs, were approved by the China Food and Drug Administration in 2004. Its main components include Astragali Radix, Ginseng Radix et Rhizoma, Aconiti Lateralis Radix Preparata, Salvia Miltiorrhiza Radix et Rhizoma, Alismatis Rhizoma, Descuraunia Semen, Cinnamomi Ramulus, Carthami Flos, Periplocae Cortex, Polygonati Odorati Rhizoma, and Citri Reticulatae Pericarpium ([@B22]; [@B61]). The favorable efficacy of QLQX in HF therapy has been confirmed by a multicentral large-scale clinical trial ([@B22]; [@B40]) and several lab experiments ([@B41]; [@B23]; [@B13]). Interestingly, QLQX has a multi-target enhancing effect on cardiac FAO, glucose oxidation, and glycolysis ([@B37]; [@B47], [@B48]), implying that QLQX might modulate substrate utilization by promoting metabolic flexibility. Thus, this study was designed to ascertain whether QLQX enabled the border and remote myocardium to choose individual optimal metabolic phenotype for improving global energetic efficiency. Glucose utilization was observed by positron emission tomography (PET), and changes in a range of metabolic enzymes were detected in both border and remote areas post-MI.

Materials and Methods {#S2}
=====================

HF Model After MI in Rats {#S2.SS1}
-------------------------

Male Sprague--Dawley rats (230--250 g) were obtained from Beijing Vital River Laboratory Animal Technology Co., Ltd. \[Animal license number: SCXK (Beijing) 2016-0006\]. HF after MI was induced surgically in rats by left anterior descending coronary artery (LAD) ligation as described previously ([@B51]; [@B55]). Briefly, following anesthesia with sodium pentobarbital (40 mg/kg intraperitoneally) and intubation, a lateral thoracotomy was carried out to access the heart. The LAD occlusion was located between the pulmonary cone and the left atrial appendage 2--3 mm from the origin, using a 5--0 proline suture. The animals were maintained for 60 days after the surgery in a 12:12 h light--dark cycle at 24°C ± 1°C and a humidity of 60 ± 10% with *ad libitum* access to standard chow and water. Following the ligation or sham operation, the surviving rats were randomly assigned to four groups: sham group (sham, *n* = 8), model group (MI, *n* = 8), QLQX group (MI + QLQX, *n* = 8), and enalapril group (MI + enalapril, *n* = 8). All experimental procedures were approved by the Animal Care and Use Committee of Beijing University of Chinese Medicine and conformed with laboratory animal management and use regulations.

Drug and Interventions {#S2.SS2}
----------------------

Qiliqiangxin capsules (A20170820) were purchased from Shijiazhuang Yiling Pharmaceutical Co., Ltd. (Shijiazhuang, Hebei, China). The high reproducibility of QLQX was clarified by a fingerprint analysis, which exhibited a high similarity of 10 batches ranging from 0.978 to 1.000 ([@B58]). Previous chemical analysis of QLQX, which was obtained from the same supplier and had the same batch number with QLQX in this study, identified the profile and concentrations of stable active ingredients ([@B11]). Enalapril was obtained from Yangzijiang Pharmaceutical Group Jiangsu Pharmaceutical Co., Ltd. (Taizhou, Jiangsu, China) as the positive control. Both the drug powder of Qiliqiangxin capsules and enalapril were dissolved in distilled water. From the second day after the surgery, Qiliqiangxin capsules and enalapril were administered for 60 days at doses of 0.514 g/(kg. d) and 2.857 mg/(kg. d), respectively (equivalent to 10 times the clinical dose), by gavage once a day. An equal volume of distilled water was administered to the sham and MI groups.

Echocardiography {#S2.SS3}
----------------

Transthoracic echocardiography was performed non-invasively 60 days after the surgery to assess LV structure and function using a Vevo 2100 high-resolution imaging system equipped with a 15-MHz transducer (VisualSonics, Toronto, Canada). Two-dimensional, M-mode parasternal echocardiograms from the long-axis view were captured for determining the ejection fraction (EF), fractional shortening (FS), LV end-systolic, and end-diastolic internal diameters (LVIDs and LVIDd), LV end-systolic and end-diastolic volumes (LVESV and LVEDV), LV end-systolic and end-diastolic anterior wall thicknesses (LVAWs and LVAWd), and LV end-systolic and end-diastolic posterior wall thicknesses (LVPWs and LVPWd).

Positron Emission Tomography {#S2.SS4}
----------------------------

Regional myocardial utilization of glucose was determined by ^18^F-fluorodeoxyglucose (^18^F-FDG)-PET using a Micro PET/computed tomography (CT) scanner (Inveon, Siemens, TN, United States). ^18^F-FDG, a glucose analog radiotracer (radiochemical purity \> 95%), was synthesized by HTA Co., Ltd. (Beijing, China). Following fasting for 15--19 h prior to imaging, the rats were subjected to FDG administration as a bolus intravenous injection via the tail vein with the mean activities of approximately 1.0 mCi. All *in vivo* imaging experiments were carried out under inhalation anesthesia using isoflurane (induced with 4% and maintained with 1.5--2% concentration). The animal was then positioned prone on the scanner bed with the heart centered in the field of view. A 10-min separate CT acquisition was performed for anatomical reference before PET scanning at 80 kV, 500 μA, and 260-ms exposure time with a thickness of 0.22 mm. Then, a static 15-min PET scan was initiated 60 min after FDG injection. The CT data were reconstructed using a cone beam Feldkamp reconstruction algorithm (COBRA) method, and PET images were reconstructed using a three-dimensional ordered subset expectation maximization (OSEM3D)/maximum *a posteriori* (MAP) algorithm (2/18 iterations) with the matrix size of 128 × 128 voxels and the requested resolution of 1.5 mm. The ^18^F-FDG uptake of LV myocardial segments was analyzed in the Inveon Research Workplace and quantified as a standardized uptake value (SUV). The PET images were re-angulated to typical heart short-axis and horizontal and vertical long-axis views and the regions of interest (ROI) were defined to the infarcted border area and the remote area ([@B41]; [@B60]).

Western Blot Analysis {#S2.SS5}
---------------------

Myocardial tissues in both the infarcted border area and remote area were homogenized in radio immunoprecipitation assay (RIPA) lysis buffer (Applygen Technologies, Beijing, China) for total cell protein extraction, followed by protein quantification using a bicinchoninic acid (BCA) protein assay kit (Applygen Technologies, Beijing, China). Equal amounts of proteins (50 μg) were separated on a 4--12% gradient sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gel and transferred onto nitrocellulose membranes in the transfer buffer. The membranes were probed with primary antibodies diluted in 5% w/v non-fat milk/Tris-buffered saline-Tween overnight at 4°C and then incubated for 1 h with appropriate horseradish peroxidase (HRP)-conjugated secondary antibodies (diluted 1:5000, Boster Biological Technology, Wuhan, China) at room temperature. The primary antibodies against glucose transporter 4 (GLUT4, 1:2000 dilution), glucose transporter 1 (GLUT1, 1:10,000 dilution), pyruvate dehydrogenase (PDH, 1:5000 dilution), phosphorylated PDH (p-PDH, 1:5000 dilution), pyruvate dehydrogenase kinase 4 (PDK4, 1:2000 dilution), lactate dehydrogenase A (LDHA, 1:1000 dilution), fatty acid translocase (FAT/CD36, 1:500 dilution), and carnitine palmitoyl transferase-1 (CPT-1, 1:500 dilution) were all from Abcam (Cambridge, United Kingdom). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (1:5000 dilution, Applygen Technologies) was measured as a loading control. Finally, proteins were visualized with an enhanced chemiluminescence kit (Beyotime Biotechnology, Jiangsu, China) and quantified using ImageJ.

Histopathologic Staining {#S2.SS6}
------------------------

Cardiac tissue specimens embedded in paraffin were cut into 3-μm-thick transverse sections, mounted on glass slides and stained with hematoxylin and eosin (H&E) to assess cardiomyocyte morphology. Immunohistochemical analysis and immunofluorescence microscopy were also performed. Immunohistochemical staining was performed to determine several important metabolic proteins in the border and remote areas. The slides were submerged in citrate solution (pH 6.0) for heat-mediated antigen retrieval and incubated with 3% hydrogen peroxide (H~2~O~2~) to block endogenous peroxidase. After blocking with non-immune goat serum, the slices were incubated with primary antibodies raised against GLUT1 (diluted 1:500), GLUT4 (diluted 1:800), LDHA (diluted 1:1500), and CD36 (diluted 1:200) overnight at 4°C, followed by incubation with an HRP-conjugated goat anti-rabbit immunoglobulin G (IgG) secondary antibody at 37°C for 30 min. The staining was then developed with a diaminobenzidine (DAB) detection kit (ZSGB-BIO, Beijing, China). Immunofluorescence staining was carried out to observe the subcellular localization of GLUT4 and GLUT1. After permeabilization with 0.1% Triton X-100 in phosphate-buffered saline (PBS), the specimens were stained with primary antibodies against GLUT4 (diluted 1:500) and GLUT1 (diluted 1:500) overnight at 4°C and a subsequent Dylight 649-conjugated goat anti-rabbit IgG secondary antibody (Abbkine Scientific Co., Ltd., Wuhan, China) at a dilution of 1:500 for 1 h at room temperature. The slides were mounted using a fluorescent mounting medium containing 4,6-diamidino-2-phenylindole (DAPI), and the images were acquired with a Leica TCS SP8X confocal microscope (Leica, Wetzlar, Germany). Leica confocal software was employed to quantify the fluorescence intensity of sarcolemma and cytosol. The results were presented as the ratio of the expression levels of GLUTs.

Determination of Lactate, Na^+^/K^+^-ATPase, and Ca^2+^-ATPase {#S2.SS7}
--------------------------------------------------------------

The lactate content and the activities of Na^+^/K^+^-ATPase and Ca^2+^-ATPase in the border-area myocardium were determined with a lactate assay kit, an Na^+^/K^+^-ATPase assay kit, and a Ca^2+^-ATPase assay kit, respectively (Nanjing Jiancheng Bioengineering Institute, Nanjing, China). The procedures were conducted in accordance with the kit instructions strictly.

Statistical Analysis {#S2.SS8}
--------------------

All data were presented as the means ± standard deviation (SD). Overall variables with normal distribution were analyzed using the Shapiro--Wilk test of normality. A one-way analysis of variance was conducted for comparisons of multiple groups, followed by pairwise comparisons with the least significant difference *post-hoc* testing or with Tamhane' T2 otherwise. The difference between mean SUVs in the border and remote areas was analyzed using a paired *t*-test. Analyses were performed with IBM SPSS Statistics 20. A *P*-value less than 0.05 was considered statistically significant.

Results {#S3}
=======

Qiliqiangxin Improved Cardiac Function and Structure in Rats With HF {#S3.SS1}
--------------------------------------------------------------------

The cardiac function and structural changes in HF rats were measured with echocardiography and H&E staining. Significant decreases in EF and FS were noted in rats with MI 8 weeks after infarction, accompanied by much higher LVIDs, LVIDd, LVESV, and LVEDV as well as lower LVAWs, LVAWd, LVPWs, and LVPWd. In response to drug treatment, QLQX ameliorated impaired EF and FS post-MI and prevented LV remodeling by reducing the diameters and volumes. Enalapril mainly improved cavity dilatation but had minimal effect on the values of EF and FS. Besides, QLQX recovered both thinned LV anterior wall and posterior wall induced by MI, but enalapril only thickened the posterior wall ([Figure 1A](#F1){ref-type="fig"}). Consistently, the morphological assessment showed that the MI group was characterized by a moderate disarrangement in the remote-area myocardium, which was rescued by both QLQX and enalapril. Also, marked necrosis of myofibrils, inflammatory infiltration, and interstitial fibrosis in the border area was relieved by only QLQX ([Figure 1B](#F1){ref-type="fig"}).

![QLQX improved cardiac structure and function 8 weeks after MI. **(A)** Echocardiography parameters in all groups (*n* = 8 per group). EF: sham: 81.85 ± 7.90%; MI: 24.21 ± 7.68%; QLQX: 36.73 ± 6.16%; enalapril: 29.16 ± 4.65%. FS: sham: 53.00 ± 8.71%; MI: 12.00 ± 4.01%; QLQX: 18.65 ± 3.49%; enalapril: 14.45 ± 2.55%. LVIDs: sham: 3.52 ± 0.98 mm; MI: 10.04 ± 1.31 mm; QLQX: 7.40 ± 0.69 mm; enalapril: 8.07 ± 0.73 mm. LVIDd: sham: 7.37 ± 0.88 mm; MI: 11.39 ± 1.14 mm; QLQX: 9.09 ± 0.71 mm; enalapril: 9.44 ± 0.80 mm. LVESV: sham: 57.11 ± 33.07 μL; MI: 580.07 ± 167.32 μL; QLQX: 292.39 ± 57.34 μL; enalapril: 354.87 ± 70.37 μL. LVEDV: sham: 291.60 ± 74.64 μL; MI: 757.30 ± 162.17 μL; QLQX: 464.14 ± 75.98 μL; enalapril: 500.73 ± 89.07 μL. LVAWs: sham: 3.58 ± 0.55 mm; MI: 0.72 ± 0.05 mm; QLQX: 1.12 ± 0.25 mm; enalapril: 0.74 ± 0.13 mm. LVAWd: sham: 1.89 ± 0.35 mm; MI: 0.73 ± 0.05 mm; QLQX: 1.11 ± 0.23 mm; enalapril: 0.78 ± 0.12 mm. LVPWs: sham: 3.37 ± 0.27 mm; MI: 2.39 ± 0.70 mm; QLQX: 3.29 ± 0.38 mm; enalapril: 3.27 ± 0.71 mm. LVPWd: sham: 2.04 ± 0.16 mm; MI: 1.64 ± 0.33 mm; QLQX: 2.27 ± 0.36 mm; enalapril: 2.48 ± 0.64 mm. **(B)** H&E staining of heart tissues in the remote area and border area. Values are means ± SD. \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001 vs. the sham group; ^\#^*P* \< 0.05, ^\#\#^*P* \< 0.01, ^\#\#\#^*P* \< 0.001 vs. the MI group.](fphys-11-00805-g001){#F1}

Qiliqiangxin Optimized the Glucose Metabolism in the Remote- and Border-Area Myocardia in Rats With HF {#S3.SS2}
------------------------------------------------------------------------------------------------------

Glucose metabolism in the myocardium was assessed using ^18^F-FDG PET/CT. The fasted sham rats showed a minimal cardiac ^18^F-FDG uptake in the remote and border areas. In comparison, a substantial uptake of ^18^F-FDG in the border area and a slight increase in the remote area were induced after MI. In the border area, a rather higher ^18^F-FDG uptake than that in rats with MI was observed in the QLQX and enalapril groups according to the mean and maximum (max) SUV with a consistent trend followed in minimum (min) SUV. However, in the remote area, the ^18^F-FDG uptake was moderately elevated by QLQX, and enalapril might exert a more obvious promoting effect primarily indicated in min SUV. The comparisons of mean SUV between the two areas in each group showed no regional difference in the sham groups, but the ^18^F-FDG uptake in the border area was much higher than that in the remote area in the MI, QLQX, and enalapril groups ([Figure 2](#F2){ref-type="fig"}).

![QLQX optimized the cardiac glucose metabolism 8 weeks after MI. The representative cardiac images of ^18^F-FDG PET/CT in all groups (remote area: white arrows; border area: yellow arrows) and the mean SUV, max SUV, and min SUV of ^18^F-FDG in the remote area (sham: 0.91 ± 0.08, 1.00 ± 0.10, and 0.82 ± 0.06, respectively, MI: 1.04 ± 0.36, 1.16 ± 0.40, and 0.93 ± 0.32, respectively, QLQX: 1.57 ± 0.41, 1.78 ± 0.48, and 1.36 ± 0.33, respectively, enalapril: 1.83 ± 0.84, 2.05 ± 0.97, and 1.58 ± 0.70, respectively) and in the border area (sham: 1.11 ± 0.25, 1.22 ± 0.29, and 1.02 ± 0.22, respectively, MI: 2.58 ± 0.19, 2.91 ± 0.23, and 2.30 ± 0.16, respectively, QLQX: 3.13 ± 0.44, 3.55 ± 0.54, and 2.65 ± 0.34, respectively, enalapril: 3.13 ± 0.53, 3.52 ± 0.61, and 2.71 ± 0.48, respectively) myocardium (*n* = 5 per group). Values are means ± SD. \**P* \< 0.05, \*\*\**P* \< 0.001 vs. the sham group; ^\#^*P* \< 0.05 vs. the MI group; ^&^*P* \< 0.05, ^&&^*P* \< 0.01, ^&&&^*P* \< 0.001 vs. the remote area.](fphys-11-00805-g002){#F2}

Qiliqiangxin Regulated GLUT1 and GLUT4 in the Remote- and Border-Area Myocardia in Rats With HF {#S3.SS3}
-----------------------------------------------------------------------------------------------

To further verify metabolic changes shown in the results of ^18^F-FDG PET, the total cell protein expression levels of GLUT4 and GLUT1 contributing to glucose uptake in the heart were determined by Western blot and immunohistochemical analyses. The results showed that MI led to a significant attenuation of insulin-sensitive GLUT4 but augmentation of insulin-insensitive GLUT1 in the border and remote areas. Following the treatment with QLQX and enalapril, the protein content of GLUT4 remained unchanged in the remote area but increased in the border area ([Figures 3A,B](#F3){ref-type="fig"}), concomitant with a great suppressive effect on GLUT1 in both areas ([Figures 3D,E](#F3){ref-type="fig"}). Subsequently, trafficking of the two glucose transporter isoforms was detected by immunofluorescence staining. The ratio of sarcolemmal and cytosolic GLUT4 in either remote or border area was dampened by MI; the ratio in the border myocardium showed significant increments in the treated groups ([Figure 3C](#F3){ref-type="fig"}). However, MI stimulated the ratio of GLUT1 localized in the sarcolemma to that in the cytoplasm in both areas, which obviously reduced in response to QLQX and enalapril, but had no significant effect in the enalapril group in the remote area ([Figure 3F](#F3){ref-type="fig"}).

![Effects of QLQX on glucose uptake transporters in infarcted hearts. **(A,D)** Western blot analysis of GLUT4 and GLUT1 protein expression in the remote area and border area (*n* = 3 or 4 per group). GLUT4: remote area: sham: 1.00 ± 0.04, MI: 0.91 ± 0.03, QLQX: 0.91 ± 0.04, enalapril: 0.91 ± 0.09; border area: sham: 1.00 ± 0.07, MI: 0.84 ± 0.04, QLQX: 0.96 ± 0.07, enalapril: 1.05 ± 0.11. GLUT1: remote area: sham: 1.00 ± 0.27, MI: 2.40 ± 0.55, QLQX: 0.90 ± 0.42, enalapril: 1.03 ± 0.23; border area: sham: 1.00 ± 0.29, MI: 2.64 ± 0.15, QLQX: 1.20 ± 0.39, enalapril: 1.32 ± 0.42. **(B,E)** Immunochemical staining of GLUT4 and GLUT1 in the remote and border areas. **(C,F)** Ratio of sarcolemmal to cytosolic expression of GLUT4 and GLUT1 and respective images of immunofluorescence confocal microscopy (indicated with arrows) in remote and border areas (*n* = 4 per group). GLUT4: remote area: sham: 1.00 ± 0.04, MI: 0.85 ± 0.02, QLQX: 0.86 ± 0.03, enalapril: 0.89 ± 0.03; border area: sham: 1.06 ± 0.03, MI: 0.79 ± 0.04, QLQX: 1.02 ± 0.05, enalapril: 1.04 ± 0.05. GLUT1: remote area: sham: 0.91 ± 0.02, MI: 1.04 ± 0.02, QLQX: 0.91 ± 0.01, enalapril: 0.94 ± 0.06; border area: sham: 0.92 ± 0.03, MI: 1.10 ± 0.04, QLQX: 0.90 ± 0.04, enalapril: 0.88 ± 0.05. **(B,E)** Immunochemical staining of GLUT4 and GLUT1 in the remote and border areas. Values are means ± SD. \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001 vs. the sham group; ^\#^*P* \< 0.05, ^\#\#^*P* \< 0.01, ^\#\#\#^*P* \< 0.001 vs. the MI group.](fphys-11-00805-g003){#F3}

Qiliqiangxin Affected the Glucose Oxidation Proteins in the Remote- and Border-Area Myocardia in Rats With HF {#S3.SS4}
-------------------------------------------------------------------------------------------------------------

PDH, the rate-limiting enzyme of glucose oxidation, is inactivated via phosphorylation by specific PDH kinase ([@B38]). Western blot analysis of the total-PDH (t-PDH) and phospho-PDH protein (p-PDH) expression in cardiac tissues helped in figuring out the glucose oxidation changes in all groups. Decreased phosphorylation of PDH, t-PDH expression (despite no statistical difference in the remote area), and ratio of p-PDH/t-PDH in both areas were found in the MI group. However, only the reduction of phospho-PDH, t-PDH, and p-PDH/t-PDH ratio in the border area rather than in the remote area was upregulated by QLQX and enalapril ([Figures 4A,B](#F4){ref-type="fig"}). Consistently, cardiac expression of PDK4, the predominant PDH kinase isoform in the heart, was significantly suppressed in the MI group in both areas, and treatment with QLQX induced PDK4 only in the border area ([Figure 4C](#F4){ref-type="fig"}).

![Effects of QLQX on glucose oxidation enzymes in infarcted hearts. **(A)** Cardiac level of p-PDH, t-PDH, and the ratio of p-PDH to t-PDH in the remote area (*n* = 4 per group). Sham: 1.00 ± 0.20, 1.00 ± 0.04, and 0.65 ± 0.18, respectively, MI: 0.41 ± 0.09, 0.82 ± 0.07, and 0.33 ± 0.20, respectively, QLQX: 0.74 ± 0.28, 0.85 ± 0.21, and 0.46 ± 0.21, respectively, enalapril: 0.91 ± 0.75, 0.75 ± 0.16, and 0.51 ± 0.17, respectively. **(B)** Cardiac level of p-PDH, t-PDH, and the ratio of p-PDH to t-PDH in the border area (*n* = 4 per group). Sham: 1.00 ± 0.36, 1.00 ± 0.02, and 0.54 ± 0.14, respectively, MI: 0.23 ± 0.12, 0.76 ± 0.10, and 0.16 ± 0.18, respectively, QLQX: 0.73 ± 0.14, 1.02 ± 0.12, and 0.45 ± 0.10, respectively, enalapril: 0.77 ± 0.50, 1.19 ± 0.16, and 0.44 ± 0.21, respectively. **(C)** Western blot analysis of PDK4 in remote and border areas (*n* = 4 per group). Remote area: sham: 1.00 ± 0.16; MI: 0.73 ± 0.11; QLQX: 0.88 ± 0.12; enalapril: 0.74 ± 0.15. Border area: sham: 1.00 ± 0.03; MI: 0.57 ± 0.01; QLQX: 0.66 ± 0.03; enalapril: 0.78 ± 0.22. Values are means ± SD. \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001 vs. the sham group;^\#^*P* \< 0.05, ^\#\#^*P* \< 0.01, ^\#\#\#^*P* \< 0.001 vs. the MI group.](fphys-11-00805-g004){#F4}

Qiliqiangxin Modulated LDHA Expression in the Remote- and Border-Area Myocardia in Rats With HF {#S3.SS5}
-----------------------------------------------------------------------------------------------

Western blot and immunochemistry examinations of LDHA were performed to further determine the glycolytic process in all groups. The results show that infarcted hearts were characterized by a marked decline in LDHA protein expression in the remote and border areas. LDHA content was induced in the border area but remained unchanged in the remote area by QLQX treatment. Meanwhile, LDHA in neither the border area nor in the remote area was influenced by enalapril ([Figures 5A,B](#F5){ref-type="fig"}).

![Effects of QLQX on anaerobic glycolytic enzymes in infarcted hearts. **(A)** Western blot analysis of LDHA protein expression in remote and border areas (*n* = 4 per group). Remote area: sham: 1.00 ± 0.11; MI: 0.72 ± 0.18; QLQX: 0.65 ± 0.13; enalapril: 0.65 ± 0.21. Border area: sham: 1.00 ± 0.07; MI: 0.72 ± 0.05; QLQX: 0.89 ± 0.07; enalapril: 0.79 ± 0.16. **(B)** Immunochemical staining of LDHA in the remote and border areas. **(C)** Contents of lactate in the border area (*n* = 6--8 per group). Sham: 0.78 ± 0.10; MI: 0.62 ± 0.10; QLQX: 0.58 ± 0.12; enalapril: 0.58 ± 0.11. **(D)** Activity of Na^+^/K^+^-ATPase and Ca^2+^-ATPase in the border area (*n* = 6--8 per group). Na^+^/K^+^-ATPase: sham: 0.33 ± 0.13; MI: 0.22 ± 0.17; QLQX: 0.30 ± 0.07; enalapril: 0.15 ± 0.10. Ca^2+^-ATPase: sham: 1.50 ± 0.67; MI: 1.82 ± 0.89; QLQX: 1.70 ± 0.41; enalapril: 2.61 ± 0.63. Values are means ± SD. \**P* \< 0.05, \*\**P* \< 0.01 vs. the sham group; ^\#^*P* \< 0.05 vs. the MI group.](fphys-11-00805-g005){#F5}

Qiliqiangxin Did Not Adversely Affect Lactate Production and Ionic Homeostasis in the Border-Area Myocardium in Rats With HF {#S3.SS6}
----------------------------------------------------------------------------------------------------------------------------

The results show that the content of lactate in the border-area cardiac tissue decreased in the MI group, but QLQX and enalapril had no effect on the content ([Figure 5C](#F5){ref-type="fig"}). A downward trend was noted for Na^+^/K^+^-ATPase of the infarcted heart. QLQX did not show obvious effects on the content, whereas the Na^+^/K^+^-ATPase activity was significantly lower in the enalapril group than in the sham rats. Meanwhile, no significant differences were observed in the Ca^2+^-ATPase of the sham, MI, and QLQX groups, and enalapril elevated cardiac Ca^2+^-ATPase activity exceeding that in the sham group ([Figures 5C,D](#F5){ref-type="fig"}).

Qiliqiangxin Influenced FA Metabolism Proteins in the Remote- and Border-Area Myocardia in Rats With HF {#S3.SS7}
-------------------------------------------------------------------------------------------------------

Moreover, the two proteins promoting FA metabolism were also determined. The infarcted heart showed a great reduction in the protein expression of CD36, a marker of FA uptake, and CPT-1, a marker of FA mitochondrial oxidation. QLQX significantly increased the expression level of CD36 and CPT-1 in the remote-area myocardium, but no difference between QLQX group and MI group was detectable in the border area. Enalapril appeared to upregulate only the CD36 expression in the border area ([Figure 6](#F6){ref-type="fig"}).

![The effects of QLQX on fatty acid uptake and oxidation proteins in failing infarcted hearts. **(A)** Western blot analysis of CD36 protein expression in remote and border areas (*n* = 4 per group). Remote area: sham: 1.00 ± 0.08; MI: 0.55 ± 0.05; QLQX: 0.80 ± 0.23; enalapril: 0.65 ± 0.18. Border area: sham: 1.00 ± 0.24; MI: 0.59 ± 0.13; QLQX: 0.77 ± 0.28; enalapril: 1.16 ± 0.33. **(B)** Immunochemical staining of CD36 in remote and border areas. **(C)** Western blot analysis of CPT-1 in remote and border areas (*n* = 4 per group). Remote area: sham: 1.00 ± 0.29; MI: 0.80 ± 0.14; QLQX: 1.34 ± 0.29; enalapril: 1.06 ± 0.18. Border area: sham: 1.00 ± 0.22; MI: 0.67 ± 0.14; QLQX: 0.59 ± 0.15; enalapril: 0.69 ± 0.19. Values are means ± SD. \**P* \< 0.05, \*\**P* \< 0.01 vs. the sham group; ^\#^*P* \< 0.05, ^\#\#^*P* \< 0.01 vs. the MI group.](fphys-11-00805-g006){#F6}

Discussion {#S4}
==========

Myocardial metabolic deterioration is the intrinsic hallmark of ischemic heart disease and HF, supporting the intriguing therapeutic perspectives of metabolic modulators ([@B9]). However, the current pharmaceutical interventions aiming at energy substrates are worth further discussion considering their preference for a specific fuel at the expense of metabolic flexibility ([@B33]). Flexibility modulation is believed to be a more accurate target despite barely matched therapy. After MI, the injured ventricle undergoes a spatial heterogeneity in structural, mechanical, and metabolic remodeling response to a pathological environment ([@B36]; [@B42]; [@B45]). Hence, compelling distinct zones preferring the same substrate seem to compromise the substrate flexibility. It may be better to treat the infarcted heart by separating it into two sections: the border area and the remote area.

QLQX has been proven to have a great potential as a promising metabolic modulator as it can regulate cardiac glucose and FA metabolism simultaneously by upregulating a large number of enzymes, including GLUT4, GLUT1, CD36, and so forth in different pathological models ([@B37]; [@B47], [@B48]). This multi-targeting regulation might depend on the multiple components identified in QLQX, encompassing ginsenoside Rb1, astragaloside, salvianolic acid A, and so forth ([@B61]). Most of these components have demonstrated an ability to target energy metabolism ([@B10]; [@B62]; [@B8]). Enalapril is a classic medication for HF, which blocks the renin--angiotensin--aldosterone system ([@B57]). It is widely believed that enalapril predominantly aims at alleviating ventricular remodeling. However, the fact that enalapril lessens cardiac workload and energy demands provides indirect evidence for its metabolism-modulating properties ([@B12]). Recently, angiotensin II has been clarified to induce a pronounced elevation in the levels of GLUT1 and a suppression of FAO enzymes, CD36, CPT-1, and so forth ([@B31], [@B32]), directly highlighting that enalapril might also be a metabolic regulator. So, with enalapril as the control intervention, the results further reveal that QLQX enabled border and remote cardiomyocytes to metabolize different substrates according to the pathological conditions to fulfill energy demands in both areas and ultimately improve LV dysfunction and LV remodeling throughout the heart.

QLQX Protected Global LV Function and Structure {#S4.SS1}
-----------------------------------------------

The echocardiography data from this study confirmed that a stable contractile dysfunction and LV dilatation occurred in the rat model of MI induced by LAD ligation for 8 weeks, consistent with previous results ([@B41]). QLQX could profoundly elevate the LV function. Both QLQX and enalapril alleviated cardiac dilatation (LVIDs, LVIDd, LVESV, and LVEDV). In the infarcted heart, LVAW and LVPW reduced, indicating an ongoing loss of viable myocardium, which originated from LVAW and progressively extended to LVPW. Both LVAW and LVPW were elevated by QLQX, whereas only LVPW was enhanced by enalapril. LVAW anatomically resembles the infarct and border areas, and LVPW equals the remote area. The results demonstrate that the myocardium in the border area was potentially salvageable and not only cells in the distal region, QLQX was also confirmed to preserve the survival cardiomyocytes closet to the scar. The morphological assessments support this conclusion.

QLQX Augmented Myocardial Glucose Uptake in the Border Area {#S4.SS2}
-----------------------------------------------------------

An infarcted heart is commonly assumed to undergo a shift from FAO to glucose metabolism. Animal micro PET/CT has helped obtain the region-specific properties of myocardial glucose uptake. In line with other studies ([@B35]; [@B60]), it has been observed that MI aroused a striking increase in glucose uptake, primarily distributed in the border area. QLQX and enalapril predominately evoked a stronger glucose entry into border cardiomyocytes but only exerted moderate effects on remote cells. The comparison of the mean SUV in the border and remote areas provided evidence that QLQX treatment favored regional differences in glucose uptake. The aforementioned glucose uptake alternations might be related to the regulation of glucose transporters. The two isoforms in human hearts, GLUT4 and GLUT1, facilitate glucose transport into cardiomyocytes by trafficking from the cytoplasm to the sarcolemma ([@B59]). In the present study, GLUT4 protein expression appeared lower, whereas GLUT1 expression markedly increased throughout the infarcted heart. In addition, the ratio of sarcolemmal to cytosolic contents of GLUT4 also significantly decreased in both areas, suggesting a weakened translocation. However, the trafficking of GLUT1 was notably stimulated, indicating that MI led to a glucose uptake increase, yet in a GLUT1-dependent manner. GLUT4 is insulin dependent and serves as the major isoform in the adult myocardium, and the insulin-insensitive GLUT1 predominates in fetal hearts ([@B43]). The transition from GLUT4 to GLUT1 has been found in ischemic and failed myocardia previously; nevertheless, the mechanism remains unknown ([@B34]; [@B35]). In the context of HF, insulin resistance weakens GLUT4 availability ([@B18]). Therefore, GLUT1 expression may increase to compensate. QLQX and enalapril did not modify GLUT4 in the remote area but upregulated GLUT4 content and translocation in the border area significantly. In addition, QLQX downregulated GLUT1 in the entire myocardium, and so did enalapril, probably because angiotensin II might be an underlying activator of GLUT1 ([@B35]). The observations implied that QLQX and enalapril promoted glucose uptake in the border area in a GLUT4-dependent manner.

Compared with FA, glucose is considered more oxygen effective because it consumes less oxygen to produce the same amount of ATP ([@B33]), making it a preferred fuel to enhance cardiac efficiency under oxygen-limited conditions. However, long-term FAO deficiency cannot be totally compensated by glucose metabolism ([@B44]). Hence, the modulation of QLQX to further stimulate glucose uptake only in the border area, which is injured more severely due to oxygen deprivation, may help in protecting against hypoxic damage without excessive glucose burden in the remote area.

QLQX Might Switch Metabolic Pathways From Glucose Oxidation to Glycolysis in the Border Area {#S4.SS3}
--------------------------------------------------------------------------------------------

Glucose is metabolized via oxidation under normoxic conditions alternatively via anaerobic glycolysis in oxygen deficits ([@B12]). Pyruvate derived from glucose is converted into acetyl-CoA for aerobic respiration by PDH which is inhibited when phosphorylated by PDH kinases, or it is converted into lactate and toward the anaerobic glycolytic pathway by LDH ([@B15]). Consistent with the changes in glucose utilization shown in PET, remarkable reductions in p-PDH expression and ratio of p-PDH/t-PDH in both border and remote areas were detected as indicative of a global enhancement in the glucose oxidative process. Concomitantly, QLQX and enalapril might prevent cardiomyocytes in the border area preferring excessive glucose oxidation, but they maintained, to some extent, the augmented glucose oxidation in the remote area, which was indicated by its promoting effect on the phosphorylation of PDH only in the border area. The concordant PDK4 changes further explained the distinct modulation of PDH in both areas with QLQX.

It is expected that an uncoupling between glycolysis and glucose oxidation and augmentation of anaerobic process are induced in HF ([@B26]). However, the present study argues an obvious absence of LDHA in both remote and border areas indicating glycolytic dysfunction. Similar results show that cardiomyocytes in the MI border zone failed to upregulate glycolysis-related genes and revert to glycolysis resembling the neonatal metabolic phenotype ([@B45]). Further, the activity of LDH in the myocardium declined in a 6-week MI rat model, suggesting abnormal anaerobic energy generation ([@B2]). QLQX exhibited a regional effect again in that it elevated the declined LDHA expression in the border area but not in the remote area. It seems that enalapril did not play a regulatory role in LDHA expression in the two areas. The lactate content and the activity of Na^+^/K^+^-ATPase and Ca^2+^-ATPase were detected to further confirm whether QLQX could cause intracellular acidosis and disturb ion homeostasis in the border area attributed to its promoting effect on glycolysis. It became evident that the lactate production in the border myocardium of rats with MI was declined, which was consistent with the debilitated LDH expression. In a similar case, the cardiac release of purines and lactate decreased in rats with MI 8 weeks after infarction, indicating attenuated sensitivity to chronic ischemia of the infarcted myocardium ([@B17]). QLQX did not increase the lactate level, and the uncoupling of LDHA expression and lactate level in the QLQX group might be due to the conducive clearance of myocardial lactic acid by the active ingredients, such as ginsenoside and astragaloside ([@B7]; [@B56]). Consequently, disordered Na^+^/K^+^-ATPase and Ca^2+^-ATPase caused by intracellular acidosis was not observed in the MI and QLQX groups. Collectively, QLQX could enhance glycolysis without deteriorating lactate production and ionic homeostasis in the border area.

Taken together, it appears that QLQX drives the infarcted heart to use different glucose metabolic pathways in discrete zones via modulating key enzymes, that is, partially keeping oxidizing glucose within the remote area while transiting oxidation to anaerobic glycolysis in the border area. To save the extremely hypoxic myocytes closest to the necrosis, the shift to anaerobic metabolism may be required for rapid energy generation without using much oxygen ([@B1]). On the contrary, for the myocardium away from the scar with better perfusion, not suppressing increased glucose oxidation contributes to less accumulation of protons and lactate from glycolysis. This advantage in terms of metabolic regulation distinguishes QLQX from enalapril. Hence, it protects the myocardium in both hypoxia-injured anterior and posterior walls.

QLQX Might Enhance FA Metabolism in the Remote Area {#S4.SS4}
---------------------------------------------------

A dramatic decrease in FAO has been observed in HF probably due to either mitochondrial capacity abnormalities ([@B28]) or compromised FAO enzymes. In keeping with this, the present findings confirm reduced expression of CD36, a transporter involved in FA uptake, and CPT-1, which assists in FA entry into mitochondria throughout the myocardium. Further, a potential regional property of QLQX regulation on FAO was noted, which preserved the reduced CD36 and CPT-1 protein contents in the border myocytes but had a strong promoting effect on these two proteins in the remote myocardium. Reversely, enalapril only upregulated the CD36 protein expression in the border area.

FA is often discarded owing to its high oxygen consumption and potential lipotoxicity when modulating cardiac substrates in HF ([@B15]). However, increasing glucose by irreversibly removing FA may not be possible ([@B14]; [@B29]), and enhancing FA preference may be an alternative phenotype to restore cardiac energetics and function ([@B16]). Considering that FA produces approximately three times the ATP per molecule compared with glucose ([@B33]), FA seems to be more efficient when oxygen is not limited in HF. Thus, stimulating FAO in the remote area may maximize energy synthesis to ensure effective functioning of myocytes. Conversely, maintaining FA utilization at a low level in the border area could avoid exacerbating hypoxic and lipotoxic injuries to the myocardium. The effects of QLQX on CD36 and CPT-1 indicate that it might exert a benign regulatory effect on cardiac FA metabolism although it requires further exploration. Enalapril has the potential to improve FA metabolism probably because angiotensin II exerts a strong suppressing effect on FAO and related genes. However, in the present study, enalapril seemed to augment only FA uptake transporter rather than the expression of FAO enzymes in the border area, implying that it was ineffective in anterior wall damage.

It is speculated that the regional metabolic regulatory advantage of QLQX might be a comprehensive outcome of its multicomponent and multi-target features. First, various components exert different regulatory effects on FAO and glycolysis. Ginsenosides, Astragaloside IV, and salsolinol, which were extracted from Ginseng Radix, Astragali Radix, and Aconiti Lateralis Radix Praeparata, in QLQX have been proven to upregulate myocardial FAO in HF ([@B20]; [@B39]; [@B6]; [@B49]). Salsolinol also could enhance glycolysis capacity, but salvianolic acid B, extracted from another herb in QLQX, inhibits cardiac glycolysis ([@B53]). It is worth noting that Astragaloside IV reduces anaerobic glycolysis in the failing heart ([@B10]), but Astragali Radix itself could increase LDH expression level in human cardiomyocytes ([@B46]), suggesting other bioactive components of Astragali Radix at work in promoting glycolysis. Second, multiple components work cooperatively. A higher salvianolic acid B concentration was found in the cardiac ischemic area than in the non-ischemic area ([@B53]). Hence, it was inferred that the distribution of other ingredients in cardiac distinct areas might also be inhomogeneous. Additionally, the regulatory effect on targets of some components also seems to have obvious regional properties in the MI heart exemplified by the effect on energy disorder induced by MI. Radix Aconiti Lateralis Preparata extract predominately optimized the distribution patterns of energy metabolism--related molecules in the non-infarct zone ([@B52]). Therefore, under different pathological conditions, the distribution of pathological targets in remote and border areas might be dissimilar, which may induce specific active ingredients to reach different regions to exert their effects.

Conclusion {#S5}
==========

In conclusion, the observations confirmed that HF did result in a shift from FAO to glucose oxidation. For better accommodation with each microenvironment and energy demands, it is possible that QLQX could encourage the border myocardium (anterior wall) to favor anaerobic glycolysis but facilitate the remote area (posterior wall) to rely more on FA metabolism by regulating respective key enzymes, probably due to its multi-target effect. This region-dependent performance reserves metabolism flexibility to ensure energy efficiency, and a decrease in the levels of toxic intermediates in the distinct area concurrently. Despite the promising findings, the exact mechanism by which QLQX optimizes cardiac substrates regionally has yet to be determined. In addition, this study only focused on the regional issue; the metabolic modulation of QLQX in different-stage HF needs further investigation.
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